FluoGuide A/S (SE:FLUO)
:FLUO
Want to see SE:FLUO full AI Analyst Report?
FLUO Stock Chart & Stats
kr36.00
-kr1.70(-3.82%)
At close: 4:00 PM EST
kr36.00
-kr1.70(-3.82%)
Day’s Range― - ―
52-Week Rangekr28.00 - kr47.60
Previous CloseN/A
Volume5.01K
Average Volume (3M)8.21K
Market Cap
kr650.70M
Enterprise Valuekr384.60M
Total Cash (Recent Filing)kr63.24M
Total Debt (Recent Filing)kr27.93M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding16,349,314
10 Day Avg. Volume11,579
30 Day Avg. Volume8,206
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)6.10
Price to Sales (P/S)0.00
P/FCF Ratio-8.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Equity And Manageable LeverageMaintaining positive equity with modest leverage provides a durable financial buffer versus creditors and gives the company time to execute clinical programs or seek partnerships. This structural balance-sheet strength supports financing flexibility and reduces immediate insolvency risk despite ongoing losses.
Very Lean, Focused TeamA seven-person organization indicates a highly focused, low-fixed-cost operating model that can concentrate R&D and regulatory efforts efficiently. Over months this enables disciplined cash deployment on core clinical priorities and makes the company less burdened by large headcount-driven fixed costs.
Free Cash Flow Burn Showing Improvement Versus Prior YearAn improving free cash flow trend, even if still negative, suggests management is beginning to slow cash outflows or realize operating efficiencies. If sustained, this reduces near-term financing needs and increases the runway to reach clinical or commercialization milestones over the coming months.
Bears Say
Material Ongoing Cash BurnVery large negative operating and free cash flows are a durable fiscal constraint: they erode reserves, force repeated external financing, and limit the company’s ability to fund clinical development internally. Persistent burn increases dilution risk and could slow program progress if capital access tightens.
Revenue Collapsed And Highly VolatileThe near-absence of recurring revenue demonstrates the company has not yet established commercial traction. Over a multi-month horizon this weakens self-funding prospects, increases reliance on external capital or milestones, and undermines the sustainability of operations without clear near-term commercialization catalysts.
Operating Losses Far Exceed Sales And Erode EquityDeep operating losses relative to negligible revenue are causing equity erosion. Continued negative returns on equity and shrinking net assets reduce financial flexibility, raise bankruptcy/dilution risk over time, and constrain the company’s ability to sustain or scale clinical and commercialization investments.
FluoGuide A/S News
FLUO FAQ
What was FluoGuide A/S’s price range in the past 12 months?
FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.60 in the past 12 months.
What is FluoGuide A/S’s market cap?
FluoGuide A/S’s market cap is kr650.70M.
When is FluoGuide A/S’s upcoming earnings report date?
FluoGuide A/S’s upcoming earnings report date is Aug 25, 2026 which is in 87 days.
How were FluoGuide A/S’s earnings last quarter?
FluoGuide A/S released its earnings results on May 27, 2026. The company reported -kr1.032 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.032.
Is FluoGuide A/S overvalued?
According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued.
Does FluoGuide A/S pay dividends?
FluoGuide A/S does not currently pay dividends.
What is FluoGuide A/S’s EPS estimate?
FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FluoGuide A/S have?
FluoGuide A/S has 16,349,314 shares outstanding.
What happened to FluoGuide A/S’s price movement after its last earnings report?
FluoGuide A/S reported an EPS of -kr1.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.687%.
Which hedge fund is a major shareholder of FluoGuide A/S?
Currently, no hedge funds are holding shares in SE:FLUO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FluoGuide A/S
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
Technical Analysis
Q-linea AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Guard Therapeutics International AB
―
Nanexa AB
―